Imunon, Inc. (IMNN)
1.58
+0.02
(+1.28%)
USD |
NASDAQ |
Sep 04, 16:00
1.57
-0.01
(-0.63%)
After-Hours: 20:00
Imunon Research and Development Expense (Quarterly) : 1.465M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.465M |
| March 31, 2026 | 2.337M |
| December 31, 2025 | 2.489M |
| September 30, 2025 | 1.899M |
| June 30, 2025 | 1.227M |
| March 31, 2025 | 2.165M |
| December 31, 2024 | 2.233M |
| September 30, 2024 | 3.293M |
| June 30, 2024 | 2.820M |
| March 31, 2024 | 3.294M |
| December 31, 2023 | 3.553M |
| September 30, 2023 | 1.981M |
| June 30, 2023 | 3.134M |
| March 31, 2023 | 2.620M |
| December 31, 2022 | 3.003M |
| September 30, 2022 | 2.409M |
| June 30, 2022 | 3.226M |
| March 31, 2022 | 3.095M |
| December 31, 2021 | 2.986M |
| September 30, 2021 | 2.468M |
| June 30, 2021 | 2.593M |
| March 31, 2021 | 2.572M |
| December 31, 2020 | 2.810M |
| September 30, 2020 | 2.492M |
| June 30, 2020 | 2.991M |
| Date | Value |
|---|---|
| March 31, 2020 | 3.052M |
| December 31, 2019 | 3.065M |
| September 30, 2019 | 3.674M |
| June 30, 2019 | 3.558M |
| March 31, 2019 | 2.768M |
| December 31, 2018 | 2.344M |
| September 30, 2018 | 2.187M |
| June 30, 2018 | 4.594M |
| March 31, 2018 | 2.741M |
| December 31, 2017 | 3.208M |
| September 30, 2017 | 3.349M |
| June 30, 2017 | 3.047M |
| March 31, 2017 | 3.475M |
| December 31, 2016 | 3.620M |
| September 30, 2016 | 4.225M |
| June 30, 2016 | 3.336M |
| March 31, 2016 | 3.441M |
| December 31, 2015 | 3.702M |
| September 30, 2015 | 2.884M |
| June 30, 2015 | 3.568M |
| March 31, 2015 | 4.506M |
| December 31, 2014 | 4.281M |
| September 30, 2014 | 4.630M |
| June 30, 2014 | 3.166M |
| March 31, 2014 | 2.893M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Phio Pharmaceuticals Corp. | 3.082M |
| Agenus, Inc. | 14.76M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |
| BioCryst Pharmaceuticals, Inc. | 51.46M |